Standort der Zentrale von Hancock Jaffe Laboratories Inc ist United States
Standort der Zentrale
Foreign companies can be traded on US stock markets and vice-versa. Obligation of foreign companies traded on US exchanges might slightly differ from obligations of domestic companies.
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.